tradingkey.logo

Myomo Inc

MYO
查看詳細走勢圖
0.928USD
+0.027+3.05%
收盤 12/19, 16:00美東報價延遲15分鐘
35.69M總市值
虧損本益比TTM

Myomo Inc

0.928
+0.027+3.05%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+3.05%

5天

-11.57%

1月

+28.96%

6月

-61.63%

今年開始到現在

-85.58%

1年

-84.83%

查看詳細走勢圖

TradingKey Myomo Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Myomo Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名91/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價5.00。中期看,股價處於平穩狀態。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Myomo Inc評分

相關信息

行業排名
91 / 208
全市場排名
216 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 5 分析師
買入
評級
5.000
目標均價
+362.96%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Myomo Inc亮點

亮點風險
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. The Company develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.
業績高增長
公司營業收入穩步增長,連續3年增長109.26%
業績增長期
公司處於發展階段,最新年度總收入32.55M美元
估值合理
公司最新PE估值-3.25,處於3年歷史合理位
機構減倉
最新機構持股21.95M股,環比減少7.73%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉712.09K股
活躍度增加
近期活躍度增加,過去20天平均換手率2.52

Myomo Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Myomo Inc簡介

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. The Company develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.
公司代碼MYO
公司Myomo Inc
CEOGudonis (Paul R)
網址https://myomo.com/

常見問題

Myomo Inc(MYO)的當前股價是多少?

Myomo Inc(MYO)的當前股價是 0.928。

Myomo Inc 的股票代碼是什麼?

Myomo Inc的股票代碼是MYO。

Myomo Inc股票的52週最高點是多少?

Myomo Inc股票的52週最高點是7.170。

Myomo Inc股票的52週最低點是多少?

Myomo Inc股票的52週最低點是0.711。

Myomo Inc的市值是多少?

Myomo Inc的市值是35.69M。

Myomo Inc的淨利潤是多少?

Myomo Inc的淨利潤為-6.18M。

現在Myomo Inc(MYO)的股票是買入、持有還是賣出?

根據分析師評級,Myomo Inc(MYO)的總體評級為買入,目標價格為5.000。

Myomo Inc(MYO)股票的每股收益(EPS TTM)是多少

Myomo Inc(MYO)股票的每股收益(EPS TTM)是-0.287。
KeyAI